-Reuters
Outlook Therapeutics To Present At The 2021 American Society Of Retina Specialists Annual Meeting
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Suber